Pharmacological enhancement of exposure-based treatment in PTSD: a qualitative review

References

• Aerni A, Traber R, Hock C, Roozendaal B, Schelling G, Papassotiropoulos A, etal. Low-dose cortisol for symptoms of posttraumatic stress disorder. American Journal of Psychiatry. 2004; 161(8): 1488–1490.
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 2013; 5th ed, Washington, DC: American Psychiatric Press.
   Google Scholar
• Arntz A, Tiesema M, Kindt M. Treatment of PTSD: A comparison of imaginal exposure with and without imagery rescripting. Journal of Behavior Therapy and Experimental Psychiatry. 2007; 38(4): 345–370.
   Web of Science ®Google Scholar
• Bisson J, Andrew M. Psychological treatment of post-traumatic stress disorder (PTSD). Cochrane Database of Systematic Reviews. 2007; 3: CD003388.
   PubMed Web of Science ®Google Scholar
• Bontempo A, Panza K. E, Bloch M. H. d-cycloserine augmentation of behavioral therapy for the treatment of anxiety disorders: A meta-analysis. Journal of Clinical Psychiatry. 2012; 73(4): 533–537.
   PubMed Web of Science ®Google Scholar
• Bouso J. C, Doblin R, Farre M, Alcazar M. A, Gomez-Jarabo G. MDMA-assisted psychotherapy using low doses in a small sample of women with chronic posttraumatic stress disorder. Journal of Psychoactive Drugs. 2008; 40(3): 225–236.
   PubMed Web of Science ®Google Scholar
• Bouton M. E. Context, time, and memory retrieval in the interference paradigms of Pavlovian learning. Psychological Bulletin. 1993; 114(1): 80–99.
   PubMed Web of Science ®Google Scholar
• Bradley R, Greene J, Russ E, Dutra L, Westen D. A multidimensional meta-analysis of psychotherapy for PTSD. American Journal of Psychiatry. 2005; 162(2): 214–227.
   PubMed Web of Science ®Google Scholar
• Brunet A, Orr S. P, Tremblay J, Robertson K, Nader K, Pitman R. K. Effect of post-retrieval propranolol on psychophysiologic responding during subsequent script-driven traumatic imagery in post-traumatic stress disorder. Journal of Psychiatric Research. 2008; 42(6): 503–506.
   PubMed Web of Science ®Google Scholar
• Brunet A, Poundja J, Tremblay J, Bui E, Thomas E, Orr S. P, etal. Trauma reactivation under the influence of propranolol decreases posttraumatic stress symptoms and disorder: 3 open-label trials. Journal of Clinical Psychopharmacology. 2011; 31(4): 547–550.
   PubMed Web of Science ®Google Scholar
• Cami J, Farre M, Mas M, Roset P. N, Poudevida S, Mas A, etal. Human pharmacology of 3,4-methylenedioxymethamphetamine (“ecstasy”): Psychomotor performance and subjective effects. Journal of Clinical Psychopharmacology. 2000; 20(4): 455–466.
   PubMed Web of Science ®Google Scholar
• Choi D. C, Rothbaum B. O, Gerardi M, Ressler K. J. Pharmacological enhancement of behavioral therapy: Focus on posttraumatic stress disorder. Current Topics in Behavioral Neurosciences. 2010; 2: 279–299.
   PubMedGoogle Scholar
• Craske M. G, Kircanski K, Zelikowsky M, Mystkowski J, Chowdhury N, Baker A. Optimizing inhibitory learning during exposure therapy. Behaviour Research and Therapy. 2008; 46(1): 5–27.
   PubMed Web of Science ®Google Scholar
• Davidson J, Pearlstein T, Londborg P, Brady K. T, Rothbaum B, Bell J, etal. Efficacy of sertraline in preventing relapse of posttraumatic stress disorder: Results of a 28-week double-blind, placebo-controlled study. American Journal of Psychiatry. 2001; 158(12): 1974–1981.
   PubMed Web of Science ®Google Scholar
• Davis H. P, Squire L. R. Protein synthesis and memory: A review. Psychological Bulletin. 1984; 96(3): 518–559.
   PubMed Web of Science ®Google Scholar
• de Kleine R. A, Hendriks G.-J, Kusters W. J. C, Broekman T. G, van Minnen A. A randomized placebo-controlled trial of d-cycloserine to enhance exposure therapy for posttraumatic stress disorder. Biological Psychiatry. 2012; 71(11): 962–968.
   PubMed Web of Science ®Google Scholar
• de Quervain D. J, Aerni A, Schelling G, Roozendaal B. Glucocorticoids and the regulation of memory in health and disease. Frontiers in Neuroendocrinology. 2009; 30(3): 358–370.
   PubMed Web of Science ®Google Scholar
• de Quervain D. J, Bentz D, Michael T, Bolt O. C, Wiederhold B. K, Margraf J, etal. Glucocorticoids enhance extinction-based psychotherapy. Proceedings of the National Academy of Sciences of the United States of America. 2011; 108(16): 6621–6625.
   PubMed Web of Science ®Google Scholar
• Debiec J, Ledoux J. E. Disruption of reconsolidation but not consolidation of auditory fear conditioning by noradrenergic blockade in the amygdala. Neuroscience. 2004; 129(2): 267–272.
   PubMed Web of Science ®Google Scholar
• Dumont G. J, Sweep F. C, van der Steen R, Hermsen R, Donders A. R, Touw D. J, etal. Increased oxytocin concentrations and prosocial feelings in humans after ecstasy (3,4-methylenedioxymethamphetamine) administration. Social Neuroscience. 2009; 4(4): 359–366.
   PubMed Web of Science ®Google Scholar
• Dumont G. J, Verkes R. J. A review of acute effects of 3,4-methylenedioxymethamphetamine in healthy volunteers. Journal of Psychopharmacology. 2006; 20(2): 176–187.
   PubMed Web of Science ®Google Scholar
• Dunlop B. W, Mansson E, Gerardi M. Pharmacological innovations for posttraumatic stress disorder and medication-enhanced psychotherapy. Current Pharmaceutical Design. 2012; 18(35): 5645–5658.
   Web of Science ®Google Scholar
• Farach F. J, Pruitt L. D, Jun J. J, Jerud A. B, Zoellner L. A, Roy-Byrne P. P. Pharmacological treatment of anxiety disorders: Current treatments and future directions. Journal of Anxiety Disorders. 2012; 26(8): 833–843.
   PubMed Web of Science ®Google Scholar
• Foa E. B, Hembree E. A, Cahill S. P, Rauch S. A. M, Riggs D. S, Feeny N. C, etal. Randomized trial of prolonged exposure for posttraumatic stress disorder with and without cognitive restructuring: Outcome at academic and community clinics. Journal of Consulting and Clinical Psychology. 2005; 73(5): 953–964.
   PubMed Web of Science ®Google Scholar
• Foa E. B, Hembree E. A, Rothbaum B. O. Prolonged exposure therapy for PTSD: Emotional processing of traumatic experiences: Therapist guide. 2007; New York: Oxford University Press.
   Google Scholar
• Foa E. B, Rothbaum B. O. Treating the trauma of rape: Cognitive-behavioral therapy for PTSD. 1998; New York: Guilford Press.
   Google Scholar
• Green A. R, Marsden C, Fone K. MDMA as a clinical tool: A note of caution. A response to Sessa and Nutt. Journal of Psychopharmacology. 2008; 22(8): 929–931.
   Web of Science ®Google Scholar
• Green A. R, Mechan A. O, Elliott J. M, O'Shea E, Colado M. I. The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, “ecstasy”). Pharmacological Reviews. 2003; 55(3): 463–508.
   PubMed Web of Science ®Google Scholar
• Guastella A, Dadds M, Lovibond P, Mitchell P, Richardson R. A randomized controlled trial of the effect of d-cycloserine on exposure therapy for spider fear. Journal of Psychiatric Research. 2007; 41(6): 466–471.
   PubMed Web of Science ®Google Scholar
• Hardman J, Limbird L. Goodman & Gilman's pharmacological basis of therapeutics. 2001; 10th ed, New York: McGraw Hill.
   Google Scholar
• Hofmann S. G, Meuret A. E, Smits J. A. J, Simon N. M, Pollack M. H, Eisenmenger K, etal. Augmentation of exposure therapy with D-cycloserine for social anxiety disorder. Archives of General Psychiatry. 2006; 63(3): 298–304.
   PubMed Web of Science ®Google Scholar
• Hysek C. M, Domes G, Liechti M. E. MDMA enhances “mind reading” of positive emotions and impairs “mind reading” of negative emotions. Psychopharmacology. 2012; 222(2): 293–302.
   PubMed Web of Science ®Google Scholar
• Hysek C. M, Simmler L. D, Nicola V. G, Vischer N, Donzelli M, Krähenbühl S, etal. Duloxetine inhibits effects of MDMA (“Ecstasy”) and in humans in a randomized placebo-controlled laboratory study. PLoS ONE. 2012; 7(5): 36476.
   PubMed Web of Science ®Google Scholar
• Johansen P. O, Krebs T. S. How could MDMA (ecstasy) help anxiety disorders? A neurobiological rationale. Journal of Psychopharmacology. 2009; 23(4): 389–391.
   PubMed Web of Science ®Google Scholar
• Kehle-Forbes S. M, Polusny M. A, MacDonald R, Murdoch M, Meis L. A, Wilt T. J. A systematic review of the efficacy of adding nonexposure components to exposure therapy for posttraumatic stress disorder. Psychological Trauma: Theory, Research, Practice, and Policy. 2012; 5(4): 317–322.
   Web of Science ®Google Scholar
• Kessler R. C, Berglund P, Demler O, Jin R, Merikangas K. R, Walters E. E. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the national comorbidity survey replication. Archives of General Psychiatry. 2005; 62(6): 593–602.
   PubMed Web of Science ®Google Scholar
• Kindt M, Soeter M. Reconsolidation in a human fear conditioning study: A test of extinction as updating mechanism. Biological Psychology. 2013; 92(1): 43–50.
   PubMed Web of Science ®Google Scholar
• Kindt M, Soeter M, Vervliet B. Beyond extinction: Erasing human fear responses and preventing the return of fear. Nature Neuroscience. 2009; 12(3): 256–258.
   PubMed Web of Science ®Google Scholar
• Kolbrich E. A, Goodwin R. S, Gorelick D. A, Hayes R. J, Stein E. A, Huestis M. A. Physiological and subjective responses to controlled oral 3,4-methylenedioxymethamphetamine administration. Journal of Clinical Psychopharmacology. 2008; 28(4): 432–440.
   PubMed Web of Science ®Google Scholar
• Kushner M, Kim S, Donahue C, Thuras P, Adson D, Kotlyar M, etal. D-cycloserine augmented exposure therapy for obsessive-compulsive disorder. Biological Psychiatry. 2007; 62(8): 835–838.
   PubMed Web of Science ®Google Scholar
• Ledgerwood L, Richardson R, Cranney J. Effects of D-cycloserine on extinction of conditioned freezing. Behavioral Neuroscience. 2003; 117(2): 341–349.
   Web of Science ®Google Scholar
• LeDoux J. E. Emotion: Clues from the brain. Annual Review of Psychology. 1995; 46: 209–235.
   PubMed Web of Science ®Google Scholar
• Liechti M. E, Baumann C, Gamma A, Vollenweider F. X. Acute psychological effects of 3,4-methylenedioxymethamphetamine (MDMA, “Ecstasy”) are attenuated by the serotonin uptake inhibitor citalopram. Neuropsychopharmacology. 2000; 22(5): 513–521.
   PubMed Web of Science ®Google Scholar
• Litz B. T, Salters-Pedneault K, Steenkamp M. M, Hermos J. A, Bryant R. A, Otto M. W, etal. A randomized placebo-controlled trial of d-cycloserine and exposure therapy for posttraumatic stress disorder. Journal of Psychiatric Research. 2012; 11: 11.
   Google Scholar
• Lonergan M. H, Olivera-Figueroa L. A, Pitman R. K, Brunet A. Propranolol's effects on the consolidation and reconsolidation of long-term emotional memory in healthy participants: A meta-analysis. Journal of Psychiatry and Neuroscience. 2012; 37(6): 120111.
   Google Scholar
• MacDonald E, Dadds M. R, Brennan J. L, Williams K, Levy F, Cauchi A. J. A review of safety, side-effects and subjective reactions to intranasal oxytocin in human research. Psychoneuroendocrinology. 2011; 36(8): 1114–1126.
   PubMed Web of Science ®Google Scholar
• Milekic M. H, Alberini C. M. Temporally graded requirement for protein synthesis following memory reactivation. Neuron. 2002; 36(3): 521–525.
   PubMed Web of Science ®Google Scholar
• Mills K. L, Teesson M, Back S. E, Brady K. T, Baker A. L, Hopwood S, etal. Integrated exposure-based therapy for co-occurring posttraumatic stress disorder and substance dependence: A randomized controlled trial. JAMA. 2012; 308(7): 690–699.
   PubMed Web of Science ®Google Scholar
• Mills K. L, Teesson M, Ross J, Peters L. Trauma, PTSD, and substance use disorders: Findings from the Australian National Survey of Mental Health and Well-Being. American Journal of Psychiatry. 2006; 163(4): 652–658.
   PubMed Web of Science ®Google Scholar
• Mithoefer M. C, Wagner M. T, Mithoefer A. T, Jerome L, Doblin R. The safety and efficacy of {+/−}3,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: The first randomized controlled pilot study. Journal of Psychopharmacology. 2011; 25(4): 439–452.
   PubMed Web of Science ®Google Scholar
• Mithoefer M. C, Wagner M. T, Mithoefer A. T, Jerome L, Martin S. F, Yazar-Klosinski B, etal. Durability of improvement in post-traumatic stress disorder symptoms and absence of harmful effects or drug dependency after 3,4-methylenedioxymethamphetamine-assisted psychotherapy: A prospective long-term follow-up study. Journal of Psychopharmacology. 2013; 27(1): 28–39.
   PubMed Web of Science ®Google Scholar
• Norberg M. M, Krystal J. H, Tolin D. F. A meta-analysis of D-cycloserine and the facilitation of fear extinction and exposure therapy. Biological Psychiatry. 2008; 63(12): 1118–1126.
   PubMed Web of Science ®Google Scholar
• Oehen P, Traber R, Widmer V, Schnyder U. A randomized, controlled pilot study of MDMA (±3,4-Methylenedioxymethamphetamine)-assisted psychotherapy for treatment of resistant, chronic Post-Traumatic Stress Disorder (PTSD). Journal of Psychopharmacology. 2013; 27(1): 40–52.
   PubMed Web of Science ®Google Scholar
• Olff M, Langeland W, Witteveen A, Denys D. A psychobiological rationale for oxytocin in the treatment of posttraumatic stress disorder. CNS Spectrum. 2010; 15(8): 522–530.
   Web of Science ®Google Scholar
• Otto M. W, Tolin D. F, Simon N. M, Pearlson G. D, Basden S, Meunier S. A, etal. Efficacy of D-cycloserine for enhancing response to cognitive-behavior therapy for panic disorder. Biological Psychiatry. 2010; 67(4): 365–370.
   PubMed Web of Science ®Google Scholar
• Parsons R. G, Ressler K. J. Implications of memory modulation for post-traumatic stress and fear disorders. Nature Neuroscience. 2013; 16(2): 146–153.
   PubMed Web of Science ®Google Scholar
• Phelps E. A, Delgado M. R, Nearing K. I, LeDoux J. E. Extinction learning in humans: Role of the amygdala and vmPFC. Neuron. 2004; 43(6): 897–905.
   PubMed Web of Science ®Google Scholar
• Powers M. B, Halpern J. M, Ferenschak M. P, Gillihan S. J, Foa E. B. A meta-analytic review of prolonged exposure for posttraumatic stress disorder. Clinical Psychology Review. 2010; 30(6): 635–641.
   PubMed Web of Science ®Google Scholar
• Resick P. A, Galovski T. E, O'Brien Uhlmansiek M, Scher C. D, Clum G. A, Young-Xu Y. A randomized clinical trial to dismantle components of cognitive processing therapy for posttraumatic stress disorder in female victims of interpersonal violence. Journal of Consulting and Clinical Psychology. 2008; 76(2): 243–258.
   PubMed Web of Science ®Google Scholar
• Ressler K. J, Rothbaum B. O, Tannenbaum L, Anderson P, Graap K, Zimand E, etal. Cognitive enhancers as adjuncts to psychotherapy: Use of D-cycloserine in phobic individuals to facilitate extinction of fear. Archives of General Psychiatry. 2004; 61(11): 1136–1144.
   PubMed Web of Science ®Google Scholar
• Richardson R, Ledgerwood L, Cranney J. Facilitation of fear extinction by D-cycloserine: Theoretical and clinical implications. Learning & Memory. 2004; 11(5): 510–516.
   PubMed Web of Science ®Google Scholar
• Rothbaum B. O, Cahill S. P, Foa E. B, Davidson J. R. T, Compton J, Connor K. M, etal. Augmentation of sertraline with prolonged exposure in the treatment of posttraumatic stress disorder. Journal of Traumatic Stress. 2006; 19(5): 625–638.
   PubMed Web of Science ®Google Scholar
• Schneier F. R, Neria Y, Pavlicova M, Hembree E, Suh E. J, Amsel L, etal. Combined prolonged exposure therapy and paroxetine for PTSD related to the World Trade Center attack: A randomized controlled trial. American Journal of Psychiatry. 2012; 169(1): 80–88.
   PubMed Web of Science ®Google Scholar
• Schnurr P. P, Friedman M. J, Engel C. C, Foa E. B, Shea M, Chow B. K, etal. Cognitive behavioral therapy for posttraumatic stress disorder in women: A randomized controlled trial. JAMA. 2007; 297(8): 820–830.
   PubMed Web of Science ®Google Scholar
• Sessa B. Is there a case for MDMA-assisted psychotherapy in the UK? (vol 21, pg 220, 2007). Journal of Psychopharmacology. 2008; 22(6): 699–699.
   Web of Science ®Google Scholar
• Siegmund A, Golfels F, Finck C, Halisch A, Räth D, Plag J, etal. D-cycloserine does not improve but might slightly speed up the outcome of in-vivo exposure therapy in patients with severe agoraphobia and panic disorder in a randomized double blind clinical trial. Journal of Psychiatric Research. 2011; 45(8): 1042–1047.
   PubMed Web of Science ®Google Scholar
• Simon N. M, Connor K. M, Lang A. J, Rauch S. A. M, Krulewicz S, LeBeau R. T, etal. Paroxetine CR augmentation for posttraumatic stress disorder refractory to prolonged exposure therapy. Journal of Clinical Psychiatry. 2008; 69(3): 400–405.
   PubMed Web of Science ®Google Scholar
• Smits J. A. J, Rosenfield D, Otto M. W, Powers M. B, Hofmann S. G, Telch M. J, etal. D-cycloserine enhancement of fear extinction is specific to successful exposure sessions: evidence from the treatment of height Phobia. Biological Psychiatry. 2013; 16(12): 01094–01093.
   Google Scholar
• Soravia L. M, Heinrichs M, Aerni A, Maroni C, Schelling G, Ehlert U, etal. Glucocorticoids reduce phobic fear in humans. Proceedings of the National Academy of Sciences of the United States of America. 2006; 103(14): 5585–5590.
   PubMed Web of Science ®Google Scholar
• Storch E. A, Merlo L. J, Bengtson M, Murphy T. K, Lewis M. H, Yang M. C, etal. D-cycloserine does not enhance exposure-response prevention therapy in obsessive-compulsive disorder. International Clinical Psychopharmacology. 2007; 22(4): 230–237.
   PubMed Web of Science ®Google Scholar
• Suris A, North C, Adinoff B, Powell C. M, Greene R. Effects of exogenous glucocorticoid on combat-related PTSD symptoms. Annals of Clinical Psychiatry. 2010; 22(4): 274–279.
   PubMed Web of Science ®Google Scholar
• Suzuki A, Josselyn S. A, Frankland P. W, Masushige S, Silva A. J, Kida S. Memory reconsolidation and extinction have distinct temporal and biochemical signatures. The Journal of Neuroscience. 2004; 24(20): 4787–4795.
   PubMed Web of Science ®Google Scholar
• Tart C. D, Handelsman P. R, Deboer L. B, Rosenfield D, Pollack M. H, Hofmann S. G, etal. Augmentation of exposure therapy with post-session administration of d-cycloserine. Journal of Psychiatric Research. 2013; 47(2): 168–174.
   PubMed Web of Science ®Google Scholar
• Thompson M. R, Callaghan P. D, Hunt G. E, Cornish J. L, McGregor I. S. A role for oxytocin and 5-HT(1A) receptors in the prosocial effects of 3,4 methylenedioxymethamphetamine (“ecstasy”). Neuroscience. 2007; 146(2): 509–514.
   PubMed Web of Science ®Google Scholar
• van Minnen A, Hagenaars M. Fear activation and habituation patterns as early process predictors of response to prolonged exposure treatment in PTSD. Journal of Traumatic Stress. 2002; 15(5): 359–367.
   PubMed Web of Science ®Google Scholar
• van Minnen A, Harned M. S, Zoellner L, Mills K. Examining potential contraindications for prolonged exposure therapy for PTSD. European Journal of Psychotraumatology. 2012; 3 18805, doi: http://dx.doi.org/10.3402/ejpt.v3i0.18805.
   Web of Science ®Google Scholar
• Walker D. L, Ressler K. J, Lu K. T, Davis M. Facilitation of conditioned fear extinction by systemic administration or intra-amygdala infusions of D-cycloserine as assessed with fear-potentiated startle in rats. Journal of Neuroscience. 2002; 22(6): 2343–2351.
   PubMed Web of Science ®Google Scholar
• Werner-Seidler A, Richardson R. Effects of D-cycloserine on extinction: Consequences of prior exposure to imipramine. Biological Psychiatry. 2007; 62(10): 1195–1197.
   Web of Science ®Google Scholar
• Yehuda R, Bierer L. M, Pratchett L, Malowney M. Glucocorticoid augmentation of prolonged exposure therapy: Rationale and case report. European Journal of Psychotraumatology. 2010; 1 5643, doi: http://dx.doi.org/10.3402/ejpt.v1i0.5643.
   Web of Science ®Google Scholar